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Abstract: A concise synthesis of the biologically active
alkaloid berberine is reported, and a versatile palladium-
catalyzed enolate arylation is used to form the isoquinoline
core. The overall yield of 50% is a large improvement over the
single, previous synthesis. By design, this modular route allows
the rapid synthesis of other members of the protoberberine
family (e.g., pseudocoptisine and palmatine) by substitution of
the readily available aryl bromide and ketone coupling
partners. Moreover, by combining enolate arylation with
in situ functionalization, substituents can be rapidly and
regioselectively introduced at the alkaloid C13 position, as
demonstrated by the total synthesis of dehydrocorydaline. The
avoidance of electrophilic aromatic substitution reactions to
make the isoquinoline allows direct access to analogues
possessing more varied electronic properties, such as the
fluorine-containing derivative synthesized here.
The isoquinoline skeleton is one of the most prevalent core
structures in alkaloid natural product chemistry. A subdivi-
sion of this class is the protoberberine alkaloids, an important
group of secondary metabolites possessing significant biolog-
ical activities as a result of their ability to bind or intercalate
DNA.[1] Isolated from an extensive range of plants, all
members feature a 5,6-dihydrodibenzo[a,g]quinolizinium
moiety (the protoberberine skeleton), typically functional-
ized with hydroxy, methoxy, and methylenedioxy substituents.
The parent compound, berberine (Scheme 1), is the most
widely distributed and intensely studied of such alkaloids,
thus having demonstrated antifungal, antibacterial, anti-
inflammatory, antimalarial, antidiabetic, and anticancer activ-
ity.[1, 2] Yet it has seen only one previous total synthesis, by
Kametani and co-workers in 1969, which provided berberine
iodide in low yield from a commercially unavailable starting
material.[3] The majority of synthetic approaches to related
compounds rely on electrophilic aromatic substitution to form
the central rings. Whilst this allows access to analogues with
electron-rich scaffolds, those with more varied electronic
properties are not readily accessible.
As we have previously reported, recent work in our
laboratories has culminated in the development of a versatile
method for the synthesis of isoquinolines.[4] This protocol
employed the palladium-catalyzed a-arylation[5] of readily
available ketones (using aryl bromides bearing an ortho-
acetal) to generate masked 1,5-dicarbonyl intermediates,
which could be cyclized with a source of NH3 to provide an
extensive array of isoquinolines in excellent yields.[6] We
therefore sought to apply this approach to the short total
synthesis of berberine and related targets. Furthermore, an
extension of our initial isoquinoline-forming methodology
introduced functional groups at the C4 position of the
isoquinoline skeleton.[7] This method exploited the fact that
the product of enolate arylation is more acidic than the
starting ketone and therefore exists as an enolate in the
reaction mixture before quenching. Consequently, this enol-
ate may be trapped in situ by a variety of alkyl, allyl, benzyl,
and heteroatom electrophiles,[8] and these are carried through
to occupy the C4 position in the resulting isoquinoline. It was
anticipated that this highly effective methodology would be
well suited to the introduction of substituents at C13 in the
protoberberine alkaloids (Scheme 1). It was envisaged that
subsequent formation of the B ring of berberine could be
achieved through nucleophilic displacement of the leaving
group X (anticipated to be chloride) by the isoquinoline
nitrogen atom.[9] The isoquinoline A in question would be
generated by aromatization of the dicarbonyl compound B,
which is the product of a palladium-catalyzed coupling
Scheme 1. Retrosynthesis of berberine and skeletally related protober-
berine natural products. PG= protecting group.
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between the aryl bromide C and the enolate of ketone D.
Trapping of the product enolate with an alkyl halide in situ
would install a functional group (R) at C13.
The synthesis of berberine commenced with the prepara-
tion of the aryl bromide 2 by methylation and acetal
protection of the commercially available benzaldehyde 1 in
98% yield over two steps (Scheme 2). Its coupling partner, 4,
was accessed by BH3 reduction of the commercially available
acid 3 and subsequent protection of the free alcohol as the
pivaloate ester. Regioselective Friedel–Crafts acylation using
Ac2O and ZnCl2 afforded 4 in 73% yield over three steps.
With the easily accessible coupling partners 2 and 4 in
hand, the key catalytic a-arylation step was investigated. The
ketone 4 was found to be unstable in the presence of NaOtBu,
but pleasingly, the milder base Cs2CO3, in combination with
5 mol% [(Amphos)2PdCl2], facilitated coupling to provide 5
in an excellent yield of 84 %. Note that the reaction was
performed in a sealed vial to allow temperature elevation to
90 8C, and to achieve full conversion of the aryl bromide it was
necessary here (and in the following arylations) to use two
equivalents of the ketone, which could be recovered easily
after the reaction was complete. However, the product 5
could still be obtained in very good yield (74 %) when using
just 1.2 equivalents of 4.
As anticipated, treating 5 with NH4Cl in EtOH/H2O at
90 8C effected hydrolysis of the acetal and subsequent
aromatization to provide the desired isoquinoline 6. How-
ever, upon workup, the characteristic bright yellow color of
berberine was obvious in the aqueous phase, thus indicating
partial displacement of pivaloate by the isoquinoline nitrogen
atom. This reactivity was therefore exploited to negate the
need for pivaloate ester cleavage and hydroxy activation.
Following formation of 6 from 5, the direct displacement of
pivaloate was promoted simply by increasing the reaction
temperature from 90 8C to 110 8C, to give a smooth one-pot
conversion into berberine in 82 % yield. Pure berberine
chloride was obtained by adding NaOH to convert the
isoquinolinium salt into its hydroxide adduct which was
extracted with CH2Cl2.
[1] Subsequent treatment with HCl
regenerated the chloride salt.
Furthermore, the miscibility of THF, EtOH, and H2O
permitted one-pot enolate arylation, isoquinoline formation,
and cyclization of the B ring, thus providing berberine
chloride from 2 and 4 in 40% yield (equivalent to 74% per
step). Hence, the synthesis of berberine chloride was achieved
in an overall yield of 68% from compound 1 (the most
valuable starting material) or 50% from compound 3 (the
longest linear sequence).
A key and advantageous feature of this modular route is
the ability to access structurally diverse alkaloids simply by
varying the aryl bromide and/or ketone coupling partners.
This modularity is exemplified in the synthesis of pseudo-
coptisine by an identical route to that used for berberine, but
starting from the alternative aryl bromide 7 (Scheme 3).
Pseudocoptisine has been shown to inhibit acetylcholinester-
ase and possesses cognitive enhancing anti-amnesic proper-
ties.[10] One other synthesis has been reported, which invloves
a photochemical enamide cyclization to form the C ring.[11]
While previously reported NMR data for pseudocoptisine
were obtained in CDCl3
[10] we found our material to be
insoluble in this solvent, as had others.[12] Data were obtained
in both [D6]DMSO and CD3OD but a close match with
literature data in CD3OD
[13] was not made (this may be
attributable to a difference in counterion, which is not
described in the literature). Therefore, a known precursor
and a tetrahydro derivative of pseudocoptisine were also
synthesized separately (see the Supporting Information for
details).[9, 14] The 1H and 13C NMR data for these compounds
were in agreement with those previously reported, and
COSY, HSQC, and HMBC analyses of our synthetic pseudo-
coptisine were fully consistent with the published structure.
Our attention turned to the total synthesis of the C13-
methylated protoberberine dehydrocorydaline,[15] which has
previously been prepared once before[16] and also semi-
synthesized by methylation of palmatine (Scheme 4).[17] It was
anticipated that the application of in situ enolate functional-
Scheme 2. Synthesis of berberine by a sequential enolate coupling,
aromatization, and cyclization sequence. Piv =pivaloyl, PTSA= para-
toluenesulfonic acid, pyr = pyridine, THF = tetrahydrofuran.
Scheme 3. Synthesis of pseudocoptisine.
.Angewandte
Communications
14556 www.angewandte.org  2014 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2014, 53, 14555 –14558
ization methodology would allow the rapid introduction of
this methyl group following enolate arylation.[7]
Before exploring this route, however, it was necessary to
obtain the appropriate ketone coupling partner 10, which was
accomplished in 76% overall yield by reduction, protection,
and regioselective Friedel–Crafts acylation of the correspond-
ing acid 9 (Scheme 4). The coupling of ketone 10 and aryl
bromide 2 required no optimization, and was successful under
identical reaction conditions to those used in the synthesis of
berberine, thus highlighting the flexibility and synthetic utility
of this route. Quenching the reaction with water provided the
ketone 11 in 93% yield, and in a single step, could be
efficiently converted into the alkaloid palmatine in 88% yield
by our one-pot aromatization/cyclization protocol.[18] Pleas-
ingly, as anticipated, in situ functionalization of the arylation
product could easily be achieved through the addition of MeI
to the reaction mixture, thus providing the a-methylated
ketone 12 in 76% yield.
Surprisingly at first, subjecting the masked 1,5-dicarbonyl
12 to the aromatization/cyclization conditions (NH4Cl, EtOH/
H2O, 90–110 8C) did not facilitate a one-pot conversion into
dehydrocorydaline (Scheme 4). It is likely that the presence
of the C4-methyl group in the isoquinoline 13 restricts
rotation about the isoquinoline–aryl bond, thereby disfavor-
ing the near planar conformation required for displacement
of pivaloate by the nitrogen atom. This hypothesis is
supported by the 1H NMR spectrum of 13, in which the CH2
protons adjacent to the A ring are diastereotopic. Reverting
to our original proposal for protoberberine synthesis, 13 could
be isolated in 94 % yield by the treating precursor 12 first with
NH4Cl, which gave a mixture of 13 and an isochromene side
product (see the Supporting Information for details), then
basification with NH4HCO3 and further heating to convert
the isochromene into 13. To introduce a more effective
leaving group and so increase the rate of cyclization, the
pivaloate ester was removed by DIBAL-H reduction. Trans-
formation of the alcohol to the chloride by the action of SOCl2
in MeCN, with subsequent solvent exchange and heating
afforded dehydrocorydaline chloride in 86 % yield over three
steps, and hence an overall yield of 47 % for the total
synthesis. The spectroscopic data for this compound were
a good match with those reported for the natural product.[15a,c]
Finally, the scope of this methodology was tested in the
preparation of an unnatural, fluorinated, protoberberine
analogue (16) by coupling the ketone 4 with aryl bromide
14 in 74 % yield (Scheme 5). The ability to access such
analogues, with tunable electronic and steric properties, is
potentially important from a medicinal chemistry perspective,
particularly those that do not contain solely electron-rich
aromatic rings. The susceptibility of the fluorinated isoquino-
line core to decomposition, presumably by nucleophilic
aromatic substitution, necessitated mild reaction conditions
for formation of the B and C rings from 15. To this end, acetal
cleavage was conducted at 60 8C, followed by in situ aroma-
tization at 90 8C, and conversion of the pivaloate ester into
a chloride leaving group in the manner described for
dehydrocorydaline. Nucleophilic displacement of chloride
by nitrogen followed rapidly in the same vessel, with no need
for solvent exchange or elevation of temperature. The
unnatural analogue 16 was obtained in 50 % yield over this
sequence from 15.
To conclude, berberine chloride was synthesized by a five-
step (longest linear sequence) route in 50 % overall yield. This
synthesis features a flexible palladium-catalyzed enolate
arylation as the key step, and hence by substitution of the
aryl bromide and ketone coupling partners, analogous
syntheses of pseudocoptisine and palmatine (in 36 % and
62% yields respectively), and of an unnatural fluorinated
analogue (in 27% yield) were readily achieved. Finally,
Scheme 4. Palladium-catalyzed enolate coupling with in situ enolate
derivatization using methyl iodide. DIBAL =diisobutylaluminum hy-
dride
Scheme 5. Formation of a fluorinated, unnatural analogue.
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enolate arylation was combined with in situ methylation to
allow rapid derivatization of the alkaloid C13 position, thus
resulting in the total synthesis of dehydrocorydaline in 47%
yield.
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